Treatment of Non‐Contained Infrabony Defects With Enamel Matrix Derivative Alone or in Combination With Biphasic Calcium Phosphate Bone Graft: A 12‐Month Randomized Controlled Clinical Trial

Losada, Meritxell; González, R Blanco; Garcia, Àngels Pujol; Santos, Antonio; Nart, José

doi:10.1902/jop.2016.160459

Cited by 25 publications

(38 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Configuration of osseous defect has been shown to be an important determinant in EMD therapy [22]. Reflecting this, in a recent study of the use of EMD in the treatment of non-contained (1- and 2-wall) infrabony defects [23], the mean CAL gain at 1 year was shown to be 2.7 mm. This CAL gain value is relatively modest, considering that the mean PD at baseline was 7.9 mm, which was much greater than the value in this study.…”

Section: Discussionmentioning

confidence: 98%

Periodontal regenerative therapy with enamel matrix derivative in the treatment of intrabony defects: a prospective 2-year study

et al. 2017

View full text Add to dashboard Cite

ObjectiveTo date, enamel matrix derivative (EMD) has been considered to be one of the few biomaterials for clinical use capable of demonstrating true periodontal regeneration. The aim of this two-center prospective clinical study was to evaluate 2-year outcome of periodontal regenerative therapy using EMD in the treatment of intrabony defects, performed as an ‘advanced medical treatment’ under the national healthcare system in Japan.ResultsPatients with chronic periodontitis who have completed initial periodontal therapy at either of the two dental school clinics were enrolled. Each contributed at least one intrabony defect of ≥3 mm in depth. During surgery, EMD was applied to the defect following debridement. Twenty-two participants (mean age 55.2 years old, 9 men and 13 women) completed 2-year reevaluation, and a total of 42 defects were subjected to data analysis. Mean gains in clinical attachment level (CAL) at 1 and 2 years were 2.9 mm (38% of baseline CAL) and 3.1 mm (41%), respectively, both showing a significant improvement from baseline. There was also a significant reduction in probing depth (PD): mean reductions at 1 and 2 years were 3.2 and 3.3 mm, respectively. There was a progressive improvement in the mean percentages of bone fill from 26% at 1 year to 36% at 2 years. No significant difference in CAL gain at 2 years was found between 3-wall bone defects and other defect types combined. In multiple regression analysis, the baseline PD was significantly associated with CAL gain at 2 years. In this population of patients, the treatment of intrabony defects with EMD yielded clinically favorable outcomes, as assessed by periodontal and radiographical parameters, over a period of 2 years.Electronic supplementary materialThe online version of this article (doi:10.1186/s13104-017-2572-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 98%

Periodontal regenerative therapy with enamel matrix derivative in the treatment of intrabony defects: a prospective 2-year study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Two treatment modalities were compared; a combined application of rhFGF‐2 + DBBM (test) and rhFGF‐2 alone (control). A sample size of 20 defects in each group was needed to achieve 80% power for detection of a clinically relevant difference in CAL gain of 1.1 mm between treatment groups, assuming a SD of 1.2 mm (Losada, González, Garcia, Santos, & Nart, ) with an alpha level 0.05 (two‐tailed). An overquotation of 10% was calculated to compensate for possible sample dropout.…”

Section: Methodsmentioning

confidence: 99%

Treatment of intrabony periodontal defects using rhFGF‐2 in combination with deproteinized bovine bone mineral or rhFGF‐2 alone: A 6‐month randomized controlled trial

Saitô

Bizenjima

Takeuchi

et al. 2019

J Clinic Periodontology

View full text Add to dashboard Cite

AimTo evaluate the use of recombinant human fibroblast growth factor (rhFGF)‐2 in combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF‐2 alone, in the treatment of intrabony periodontal defects.Materials and MethodsPatients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rhFGF‐2 + DBBM (test) or rhFGF‐2 alone (control). Clinical parameters and a patient‐reported outcome measure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively.ResultsTwenty‐two sites in each group were evaluated. A significant improvement in clinical attachment level (CAL) from baseline was observed in both groups at 6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in PROM between groups was observed.ConclusionsAt 6 months, no significant difference in CAL gain or PROM between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.

show abstract

“…In addition to appropriate cells and scaffolds, biological signals are necessary for tissue regeneration . Enamel matrix derivative (EMD) has been shown to promote regeneration of periodontal tissues, and the clinical effectiveness of regenerative therapy using EMD is well documented . EMD is a porcine‐derived material that is essentially composed of acid‐extracted amelogenins in a viscous aqueous solution.…”

Section: Introductionmentioning

confidence: 99%

“…11 Enamel matrix derivative (EMD) has been shown to promote regeneration of periodontal tissues, 15 and the clinical effectiveness of regenerative therapy using EMD is well documented. [16][17][18][19] EMD is a porcine-derived material that is essentially composed of acid-extracted amelogenins in a viscous aqueous solution. EMD has growth-factor-like activity that enhances cell proliferation, migration, adhesion and differentiation.…”

Section: Introductionmentioning

confidence: 99%

Effect of the combined use of enamel matrix derivative and atelocollagen sponge scaffold on osteoblastic differentiation of mouse induced pluripotent stem cells in vitro

Hisanaga

Suzuki

Aoki

et al. 2017

J of Periodontal Research

View full text Add to dashboard Cite

show abstract

Treatment of Non‐Contained Infrabony Defects With Enamel Matrix Derivative Alone or in Combination With Biphasic Calcium Phosphate Bone Graft: A 12‐Month Randomized Controlled Clinical Trial

Cited by 25 publications

References 44 publications

Periodontal regenerative therapy with enamel matrix derivative in the treatment of intrabony defects: a prospective 2-year study

Periodontal regenerative therapy with enamel matrix derivative in the treatment of intrabony defects: a prospective 2-year study

Treatment of intrabony periodontal defects using rhFGF‐2 in combination with deproteinized bovine bone mineral or rhFGF‐2 alone: A 6‐month randomized controlled trial

Effect of the combined use of enamel matrix derivative and atelocollagen sponge scaffold on osteoblastic differentiation of mouse induced pluripotent stem cells in vitro

Contact Info

Product

Resources

About